Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » By Affiliations
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top 20 Journal Cited
 » Top 20 Cited
 » Top 20 Author Cited
 » Usage Since Sept 2007


 
 
 

Login | Create Account

p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma

Khalid Ahmad Puaat, and Wan Muhaizan Wan Mustaffa, and Phang, Koon Seng, and Arni Talib, (2006) p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma. Malaysian Journal of Pathology, 28 (2). pp. 93-99. ISSN 0126-8635

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1533Kb

Official URL: http://www.mjpath.org.my

Affiliations

Universiti Kebangsaan Malaysia. Faculty of Medicine. Dept. of Pathology
Kuala Lumpur General Hospital. Dept. of Pathology

Abstract

Objectives: This study was carried out to determine the role of p53 and p21 in the pathogenesis of prostatic adenocarcinoma and their association with tumour grade. Method: Sixty-seven histologically confirmed prostatic adenocarcinoma cases collected from Hospital Universiti Kebangsaan Malaysia and General Hospital Kuala Lumpur were studied. The formalin-fixed paraffin-embedded tissues were stained with monoclonal antibody p53 (clone DO-7) and p21 (clone SX II8) using standard avidin-biotin complex immunohistochemistry (IHC) after microwave antigen retrieval. The adenocarcinomas were graded histologically according to Gleason score: low grade = score 2-4, intermediate grade = score 5-7, high grade = score 8-10. Histological grade was analysed against IHC expressions of p53 and p21 and against patient age and ethnicity. Results: IHC positivity for p53 was expressed in 1/2 (50%) low grade, 14/33 (42%) intermediate grade, and 21/32 (66%) high grade tumours. p21 was expressed in 0/2 low grade, 16/33 (48%) intermediate grade and 15/32 (47%) high grade tumours. p53 and p21 expressions did not show statistically significant correlation with the different grades of prostatic adenocarcinoma or with each other (p=0.42). There was no correlation between tumour grade and age or ethnicity. Conclusion: Although the p53 positivity rate was higher in high-grade prostate adenocarcinoma, this was not statistically significant. We found that a combined expression of p21 and p53 was not correlated with tumour grade. We could not confirm that p21 expression was dependent on p53 expression.

Item Type:Journal
Keywords:p53, p21, prostate cancer, Gleason grade.
Subjects:R Medicine
ID Code:1768

Diller L, Kassal J, Nelson CE, et al. p53 function as a cell cycle arrest control protein in osteosarcoma. Mol Cell Biol 1990; 10:5772-81.

Gousse AE, Slawin K, Wheeler T, Scardino PT, Thompson TC. A novel approach for detecting p53 mutations in heterogeneous prostate tissue samples using TA-cloning-PCR-SSCP. J Urol 1994; 151:471A.

Baker SJ, Markonita S, Fearon ER, Wilson JKU, Volgestein B. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 1990; 249:912-5.

Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumour-derived cell line. Proct Natl Acad Sci USA 1992; 89: 4495-9.

Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-6.

Byrne RL, Wilson CH, Robinson MC, Antzen P et al. The expression of Waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997; 79: 190-5.

Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253: 49-53.

Effert PJ, McCoy RH, Walther PJ, et al. p53 gene alterations in human prostate carcinoma. J Urol 1993; 150: 257-61.

Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85:1657-69.

Bookstein R, MacGrogan D, Hilsenbeck SG, et al. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53:3369-73.

Adsay V, Sakr W, Grignon D, Frank J, Crissman J, Sarkar F. Distribution of WAF1 in normal and neoplastic prostate tissue. Lab Invest 1997; 76: 68.

Iman O, Marija D, Melissa F, Joseph F, Howard IS, Carlos CC. Inactivation of the p53 pathway in prostate cancer : Impact on tumour progression. Clin Cancer Res 1999; 5 : 2082 – 8.

Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinoma: evidence of p53-independent expression

and association with tumoral differentiation. Oncogene 1996;12: 1319–24

Qin LF, Ng IOL, Fan ST, Ng M. p21, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998; 79: 424–8

Erber R, Klein W, Andl T, et al. Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 1997;74: 383–9.

Hisashi M, Takeshi S, Toshikata G, Yoshio H, Yukio H, Tadaichi K, Kazuki K, Atsuhiko S, Toshikazu M, Rikuo M. Immunohistochemical study of p21WAF1 and p53 proteins in Prostatic Cancer and their prognostic significance. Hum Pathol 1998; 29: 778 – 83.

Sinicrope FA, Roddey G, Lemoine M, Ruan S, Stephen LC, Frazier ML, Shen Y, Zhang W. Loss of p21/ Waf-1/ Cip-1 in primary bladder tumours. Oncol Res 1996; 8: 409-14.

Repository Staff Only: item control page
 
 
 
 
 
   
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.